Maritza Mosella
YOU?
Author Swipe
View article: OS01.7.A Detection of methylation-based prognostic signatures in liquid biopsy specimens from patients with meningiomas
OS01.7.A Detection of methylation-based prognostic signatures in liquid biopsy specimens from patients with meningiomas Open
Background Detection of distinct epigenetic biomarkers in circulating cell-free DNA (cfDNA) of liquid biopsy (LB) specimens (e.g. blood) fosters opportunity for prognostication of central nervous system (CNS) tumors and has not been thorou…
View article: Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors
Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors Open
Background DNA methylation abnormalities are pervasive in pituitary neuroendocrine tumors (PitNETs). The feasibility to detect methylome alterations in circulating cell-free DNA (cfDNA) has been reported for several central nervous system …
View article: EPCO-30. MACHINE-LEARNING PREDICTIVE MODELS BASED ON DNA METHYLATION SIGNATURES DETECTED IN LIQUID BIOPSY SPECIMENS ACCURATELY PREDICT THE DIAGNOSIS AND PROGNOSIS OF MENINGIOMAS
EPCO-30. MACHINE-LEARNING PREDICTIVE MODELS BASED ON DNA METHYLATION SIGNATURES DETECTED IN LIQUID BIOPSY SPECIMENS ACCURATELY PREDICT THE DIAGNOSIS AND PROGNOSIS OF MENINGIOMAS Open
BACKGROUND Detection of distinct epigenetic features in circulating cell-free DNA (cfDNA) of liquid biopsy specimens (e.g. blood) provides an opportunity to diagnose and prognosticate central nervous system (CNS) tumors. Utilization of dis…
View article: OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups
OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups Open
Background Tumor-infiltrating immune cell compositions have been previously correlated to encouragement or inhibition of tumor growth. This association highlights immune-landscape profiling through non-invasive methods as a crucial step in…
View article: A serum-based DNA methylation assay provides accurate detection of glioma
A serum-based DNA methylation assay provides accurate detection of glioma Open
Background The detection of somatic mutations in cell-free DNA (cfDNA) from liquid biopsy has emerged as a noninvasive tool to monitor the follow-up of cancer patients. However, the significance of cfDNA clinical utility remains uncertain …
View article: Detection of Circulating Tumor-specific DNA Methylation Markers in the Blood of Patients with Pituitary Tumors
Detection of Circulating Tumor-specific DNA Methylation Markers in the Blood of Patients with Pituitary Tumors Open
Genome-wide DNA methylation aberrations are pervasive and associated with clinicopathological features across pituitary tumors (PT) subtypes. The feasibility to detect CpG methylation abnormalities in circulating cell-free DNA (cfDNA) has …
View article: OR32-03 Serum Cell-Free Methylation-Based Signatures Distinguishes Pituitary Tumors According to Functional Status and from Other Neoplasia: A Liquid Biopsy Approach
OR32-03 Serum Cell-Free Methylation-Based Signatures Distinguishes Pituitary Tumors According to Functional Status and from Other Neoplasia: A Liquid Biopsy Approach Open
BACKGROUND: Several reports have indicated that distinct epigenomic patterns of pituitary tumors (PT), specifically DNA methylation, distinguish these tumor tissues according to their functionality and could be involved in their pathogenes…
OS1.5 Detection of glioma and prognostic subtypes by non-invasive circulating cell-free DNA methylation markers Open
BACKGROUND: Genome-wide DNA methylation profiling has shown that epigenetic abnormalities are biologically important in glioma and can be used to classify these tumors into distinct prognostic groups. Thus far, DNA profiling has required s…
View article: P01.02 Serum-derived DNA methylation markers distinguish functional and invasiveness subtypes in patients harboring pituitary tumors
P01.02 Serum-derived DNA methylation markers distinguish functional and invasiveness subtypes in patients harboring pituitary tumors Open
BACKGROUND Molecular profiling of circulating biomarkers released by tumors has a relevant clinical value in central nervous system (CNS) tumors, but its feasibility has not been investigated in pituitary tumors (PT) despite being the seco…
View article: Detection of glioma and prognostic subtypes by non-invasive circulating cell-free DNA methylation markers
Detection of glioma and prognostic subtypes by non-invasive circulating cell-free DNA methylation markers Open
SUMMARY Genome-wide DNA methylation profiling has shown that epigenetic abnormalities are biologically important in glioma and can be used to classify these tumors into distinct prognostic groups. Thus far, DNA profiling has required surgi…
View article: OR24-5 Aberrant DNA Methylation in Regulatory Genomic Elements Are Associated with Invasive Behavior of Pituitary Macroadenomas: An Integrative Analysis of Epigenome-Wide Studies
OR24-5 Aberrant DNA Methylation in Regulatory Genomic Elements Are Associated with Invasive Behavior of Pituitary Macroadenomas: An Integrative Analysis of Epigenome-Wide Studies Open
A significant proportion of pituitary tumors (PT) invade adjacent structures. Few putative somatic mutations or copy number alterations have been associated with PT invasiveness. DNA methylation abnormalities in regulatory regions are know…
View article: GENE-07. GENOMIC ENHANCER METHYLATION IS ASSOCIATED WITH BIOLOGICAL AND CLINICAL FEATURES IN PITUITARY TUMORS
GENE-07. GENOMIC ENHANCER METHYLATION IS ASSOCIATED WITH BIOLOGICAL AND CLINICAL FEATURES IN PITUITARY TUMORS Open
The importance of enhancers has been recently highlighted in a pan-can transcriptomic analysis that revealed causal interaction between active enhancers and actionable genes as well as their prognostic value. DNA methylation is associated …